| Metric | Value ($ M) |
|---|---|
| Revenue | 0.02 |
| Total Income | 0.02 |
| Expenditure | 4.63 |
| PBT | — |
| Net Profit | -4.22 |
| OPM | — |
| NPM | — |
| EPS | -0.14 |
Senti Bio Reports Q1 2026 Results; Highlights SENTI-202 Program Advancement
14 May 2026 · 14 May, 6:21 pm
Summary
Senti Biosciences Holdings reported financial results for the first quarter ended March 31, 2026. The company highlighted the advancement of the SENTI-202 program into a pivotal phase and secured a strategic financing vehicle for up to $40 million. The FDA provided positive feedback supporting a single-arm pivotal trial for potential registration of SENTI-202 in R/R AML. The company also reported a reduced quarterly net loss and cash burn due to continued operational streamlining. Cash and cash equivalents were $8.9 million as of March 31, 2026.
Key Highlights
- 1
Senti Bio secured a strategic financing vehicle for up to $40 million.
- 2
The FDA provided positive feedback supporting a single-arm pivotal trial for potential registration of SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).
- 3
Operational streamlining contributed to a substantially reduced quarterly net loss and cash burn.
- 4
Research and development expenses decreased to $5.3 million for the first quarter of 2026, compared to $9.3 million for the same period in 2025.
- 5
General and administrative expenses decreased to $6.2 million for the first quarter of 2026, compared to $7.1 million for the same period in 2025.
- 6
Net loss was $4.2 million, or $0.14 per basic and diluted share, for the first quarter of 2026, compared to a net loss of $14.1 million, or $1.41 per basic and diluted share, for the first quarter of 2025.
- 7
Net cash used in operating activities was $7.5 million during the first quarter of 2026, compared to $14.1 million during the same period in 2025.
Management Comments
Timothy Lu
“We entered 2026 with a clear focus on advancing SENTI-202 and extending our operational runway while positioning the company for its next phase of clinical development,” “Since the start of the year, we have made meaningful progress across each of these priorities, including a positive regulatory engagement with the FDA on SENTI-202 - a Regenerative Medicine Advanced Therapy (RMAT) designated product - regarding the study design for the planned pivotal trial, execution of a strategic financing agreement that could provide up to $40 million in capital, and continued reductions in operating expenses and cash burn.” “We believe the recent FDA interactions and feedback represent an important milestone for the program and further support the potential of SENTI-202 in relapsed/refractory hematologic malignancies. We remain focused on advancing SENTI-202 efficiently toward the next stage of pivotal development in R/R AML and exploring future combinations with standard of care chemotherapy in newly diagnosed AML patients. We also aim to use our differentiated gene circuit platform to create therapies for additional ex vivo and in vivo CAR therapies.” “This positive FDA RMAT meeting marks a transformational moment for Senti Bio and significantly advances our path toward potential registration of SENTI-202.”
Kanya Rajangam
“The FDA feedback provides important clarity around our registrational development strategy and further supports our conviction in the SENTI-202 program,” “The excellent clinical activity observed thus far, including MRD-negative durable complete remissions alongside a favorable safety profile, gives us confidence as we transition toward later-stage development. We are focused on rapidly implementing the pivotal study while also exploring potential expansion opportunities in newly diagnosed AML and pediatric AML. Since the filing of our IND, Senti has focused on donor selection to minimize variability. We are in a strong position as we prepare for our clinical trials with the identification of a donor phenotype that correlates with increased activity and continues to support SENTI-202’s allogeneic manufacturing.”
Informational and educational content only. Not investment advice.